Fourth European Conference on Infections in Leukaemia (ECIL-4)

Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

Andreas H. Groll*, Elio Castagnola, Simone Cesaro, Jean Hugues Dalle, Dan Engelhard, William Hope, Emmanuel Roilides, Jan Styczynski, Adilia Warris, Thomas Lehrnbecher

*Corresponding author for this work

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from differences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript.

Original languageEnglish
Pages (from-to)E327-E340
Number of pages14
JournalThe Lancet Oncology
Volume15
Issue number8
Early online date29 Jun 2014
DOIs
Publication statusPublished - Jul 2014

Fingerprint

Mycoses
Stem Cell Transplantation
Leukemia
Guidelines
Pediatrics
Infection
Neoplasms
Literature
Therapeutics
Phase III Clinical Trials
Antifungal Agents
Comorbidity
Epidemiology
Pharmacology
Morbidity
Mortality

ASJC Scopus subject areas

  • Oncology

Cite this

Fourth European Conference on Infections in Leukaemia (ECIL-4) : Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. / Groll, Andreas H.; Castagnola, Elio; Cesaro, Simone; Dalle, Jean Hugues; Engelhard, Dan; Hope, William; Roilides, Emmanuel; Styczynski, Jan; Warris, Adilia; Lehrnbecher, Thomas.

In: The Lancet Oncology, Vol. 15, No. 8, 07.2014, p. E327-E340.

Research output: Contribution to journalArticle

Groll, Andreas H. ; Castagnola, Elio ; Cesaro, Simone ; Dalle, Jean Hugues ; Engelhard, Dan ; Hope, William ; Roilides, Emmanuel ; Styczynski, Jan ; Warris, Adilia ; Lehrnbecher, Thomas. / Fourth European Conference on Infections in Leukaemia (ECIL-4) : Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. In: The Lancet Oncology. 2014 ; Vol. 15, No. 8. pp. E327-E340.
@article{f411eda724714cf79a4de35b1dbd7116,
title = "Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation",
abstract = "Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from differences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript.",
author = "Groll, {Andreas H.} and Elio Castagnola and Simone Cesaro and Dalle, {Jean Hugues} and Dan Engelhard and William Hope and Emmanuel Roilides and Jan Styczynski and Adilia Warris and Thomas Lehrnbecher",
note = "We are indebted to the other scientifi c faculty of the ECIL-4 meeting: Hamdi Akan, Murat Akova (Turkey); Dina Averbuch (Israel); Rose-Mary Barnes (UK); Nicole Blijlevens (Netherlands); Thierry Calandra (Switzerland); Catherine Cordonnier (France); Oliver Cornely (Germany); Rafael de la Camara (Spai); Peter Donnelly (Netherlands); Lubos Drgona (Slovakia); Hermann Einsele (Germany); Bertrand Gachot (France); Corrado Girmenia (Italy); Ingeborg Gyssens (Netherlands); Werner Heinz (Germany); Raoul Herbrecht (France); Hans Hirsch (Switzerland); Petr Hubacek (Czech Republic); Chris Kibbler (UK); Galina Klyasova (Russia); Michal Kouba (Czech Republic); Catherine Lagrou (Belgium); Per Ljungman (Sweden); Johan Maertens (Belgium); Oscar Marchetti (Switzerland); Rodrigo Martino (Spain); Georg Maschmeyer (Germany); Tamas Masszi (Hungary); Suzanne Matthes-Martin (Austria); Malgorzata Mikulska, Alessandra Micozzi (Italy); Bilal Mohty (Switzerland); Patricia Munoz (Spain); David Nadal (Switzerland); Christina Orasch (Switzerland); Zdenek Racil (Czech Republic); Patricia Ribaud (France); Janos Sinko (Hungary); Alina Tanase (Hungary); Mario Tumbarello (Italy); Paul Verweij (Netherlands); Claudio Viscoli (Italy); Kate-Nora Ward (UK). We also thank the staff of KOBE, group GL Events, Lyon, France, for the organisation of the meeting. The ECIL-4 meeting in Sept 9–10, 2011, was supported by unrestricted educational grants of Astellas Pharma, Gilead Sciences, Merck & Co, and Pfi zer. Astellas Pharma, Gilead Sciences, Merck & Co, and Pfi zer had no role in the selection of experts and the design of the guideline; in the collection, analysis, and interpretation of the data at any time including the consensus conference; in the writing and editing of the guideline; or in the decision to submit it for publication.",
year = "2014",
month = "7",
doi = "10.1016/S1470-2045(14)70017-8",
language = "English",
volume = "15",
pages = "E327--E340",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "8",

}

TY - JOUR

T1 - Fourth European Conference on Infections in Leukaemia (ECIL-4)

T2 - Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

AU - Groll, Andreas H.

AU - Castagnola, Elio

AU - Cesaro, Simone

AU - Dalle, Jean Hugues

AU - Engelhard, Dan

AU - Hope, William

AU - Roilides, Emmanuel

AU - Styczynski, Jan

AU - Warris, Adilia

AU - Lehrnbecher, Thomas

N1 - We are indebted to the other scientifi c faculty of the ECIL-4 meeting: Hamdi Akan, Murat Akova (Turkey); Dina Averbuch (Israel); Rose-Mary Barnes (UK); Nicole Blijlevens (Netherlands); Thierry Calandra (Switzerland); Catherine Cordonnier (France); Oliver Cornely (Germany); Rafael de la Camara (Spai); Peter Donnelly (Netherlands); Lubos Drgona (Slovakia); Hermann Einsele (Germany); Bertrand Gachot (France); Corrado Girmenia (Italy); Ingeborg Gyssens (Netherlands); Werner Heinz (Germany); Raoul Herbrecht (France); Hans Hirsch (Switzerland); Petr Hubacek (Czech Republic); Chris Kibbler (UK); Galina Klyasova (Russia); Michal Kouba (Czech Republic); Catherine Lagrou (Belgium); Per Ljungman (Sweden); Johan Maertens (Belgium); Oscar Marchetti (Switzerland); Rodrigo Martino (Spain); Georg Maschmeyer (Germany); Tamas Masszi (Hungary); Suzanne Matthes-Martin (Austria); Malgorzata Mikulska, Alessandra Micozzi (Italy); Bilal Mohty (Switzerland); Patricia Munoz (Spain); David Nadal (Switzerland); Christina Orasch (Switzerland); Zdenek Racil (Czech Republic); Patricia Ribaud (France); Janos Sinko (Hungary); Alina Tanase (Hungary); Mario Tumbarello (Italy); Paul Verweij (Netherlands); Claudio Viscoli (Italy); Kate-Nora Ward (UK). We also thank the staff of KOBE, group GL Events, Lyon, France, for the organisation of the meeting. The ECIL-4 meeting in Sept 9–10, 2011, was supported by unrestricted educational grants of Astellas Pharma, Gilead Sciences, Merck & Co, and Pfi zer. Astellas Pharma, Gilead Sciences, Merck & Co, and Pfi zer had no role in the selection of experts and the design of the guideline; in the collection, analysis, and interpretation of the data at any time including the consensus conference; in the writing and editing of the guideline; or in the decision to submit it for publication.

PY - 2014/7

Y1 - 2014/7

N2 - Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from differences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript.

AB - Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT). Apart from differences in underlying disorders and comorbidities relative to those of adults, IFDs in infants, children, and adolescents are unique with respect to their epidemiology, the usefulness of diagnostic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional phase 3 clinical trials for guidance of evidence-based decisions. To better define the state of knowledge on IFDs in paediatric patients with cancer and allogeneic HSCT and to improve IFD diagnosis, prevention, and management, the Fourth European Conference on Infections in Leukaemia (ECIL-4) in 2011 convened a group that reviewed the scientific literature on IFDs and graded the available quality of evidence according to the Infectious Diseases Society of America grading system. The final considerations and recommendations of the group are summarised in this manuscript.

UR - http://www.scopus.com/inward/record.url?scp=84903465253&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70017-8

DO - 10.1016/S1470-2045(14)70017-8

M3 - Article

VL - 15

SP - E327-E340

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 8

ER -